{
    "nct_id": "NCT02733159",
    "official_title": "A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2",
    "criteria": {
        "raw_text": "Core Inclusion Criteria:\n\n* Histologically confirmed PD-L1 status defined NSCLC. Biopsy must be within 70 days of first treatment with pembrolizumab.\n* ECOG performance status 2.\n* Life expectancy \\> 12 weeks.\n* Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1\n* Computerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab.\n* Adequate haematological function:\n\n  * Platelet count ≥100 x 109 /L.\n  * Neutrophils ≥1.5 x 109/L.\n  * Haemoglobin ≥ 90 g/L.\n* Adequate hepatic function:\n\n  * Serum bilirubin ≤1.5 x upper limit of normal (ULN).\n  * Serum transaminases ≤2.5 x ULN.\n* Adequate renal function: Creatinine clearance \\<1.5 times ULN concurrent with creatinine clearance \\>50 ml/min.\n* Provision of signed and dated, written informed consent prior to any trial specific procedures, sampling and analyses.\n\nCore Exclusion Criteria:\n\n* Patients who do not meet the criteria of performance status = 2 on the ECOG Performance scale.\n* Untreated symptomatic brain or leptomeningeal metastatic disease.\n* Medical or psychiatric conditions compromising informed consent.\n* Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.\n* Radiotherapy within 28 days of trial treatment.\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* Chronic usage of steroids or other immunosuppressant medication.\n* Previous history of pneumonitis.\n* Any evidence of clinical autoimmunity.\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Histologically confirmed PD-L1 status defined NSCLC. Biopsy must be within 70 days of first treatment with pembrolizumab.\n* ECOG performance status 2.\n* Life expectancy > 12 weeks.\n* Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1\n* Computerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab.\n* Adequate haematological function:\n  * Platelet count ≥100 x 109 /L.\n  * Neutrophils ≥1.5 x 109/L.\n  * Haemoglobin ≥ 90 g/L.\n* Adequate hepatic function:\n  * Serum bilirubin ≤1.5 x upper limit of normal (ULN).\n  * Serum transaminases ≤2.5 x ULN.\n* Adequate renal function: Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min.\n* Provision of signed and dated, written informed consent prior to any trial specific procedures, sampling and analyses.\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "exclusion": "* Patients who do not meet the criteria of performance status = 2 on the ECOG Performance scale.\n* Untreated symptomatic brain or leptomeningeal metastatic disease.\n* Medical or psychiatric conditions compromising informed consent.\n* Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.\n* Radiotherapy within 28 days of trial treatment.\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* Chronic usage of steroids or other immunosuppressant medication.\n* Previous history of pneumonitis.\n* Any evidence of clinical autoimmunity."
    }
}